TimothyJO'RourkeMD

PubMed

• 5 citations
  Effect of single agent high-dose methotrexate-related acute kidney injury on length of hospitalization and relative dose intensity in adult patients with central nervo...
  Jennifer S Steward, Heather Bullard, Timothy J O'Rourke, Alan D Campbell, Brett T Brinker, Kathleen J Yost, Amy C Vanderwoude, William L Scott, Polly E Kintzel> ;Journal of Oncology Pharmacy Practice. 2017 Oct 1
• 304 citations
  First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers.
  Branimir I. Sikic, Nehal Lakhani, Amita Patnaik, Sumit A. Shah, Sreenivasa R Chandana, Drew W. Rasco, A. Dimitrios Colevas, Timothy J. O'Rourke, Sujata Narayanan, Kyri...> ;Journal of Clinical Oncology. 2016 May 20
• 10 citations
  Development of a Center for Personalized Cancer Care at a Regional Cancer Center: Feasibility Trial of an Institutional Tumor Sequencing Advisory Board.
  Brian R. Lane, Jeffrey Bissonnette, Tracy L. Waldherr, Deborah Ritz-Holland, Dave Chesla, Sandra Cottingham, Sheryl Alberta, Cong Liu, Amanda B. Thompson, Carrie R. Gr...> ;The Journal of Molecular Diagnostics. 2015 Nov 1
• 101 citations
  Hepatocyte growth factor (HGF) autocrine activation predicts sensitivity to MET inhibition in glioblastoma
  Qian Xie, Robert D. Bradley, Liang Kang, Julie Koeman, Maria Libera Ascierto, Andrea Worschech, Valeria De Giorgi, Ena Wang, Lisa Kefene, Yanli Su, Curt J. Essenburg, ...> ;Proceedings of the National Academy of Sciences of the United States of America. 2012 Jan 10
• 12 citations
  Reduced time for urinary alkalinization before high-dose methotrexate with preadmission oral bicarbonate.
  Polly E Kintzel, Alan D. Campbell, Kathleen J. Yost, Brett T Brinker, Nicole V Arradaza, Daniel Frobish, Alison M Wehr, Timothy J. O'Rourke> ;Journal of Oncology Pharmacy Practice. 2012 Jun 1
• 30 citations
  Cost savings from dose rounding of biologic anticancer agents in adults.
  Brenda J Winger, Elizabeth A. Clements, Jaculin L. DeYoung, Timothy J O'Rourke, Deborah L Claypool, Steve Vachon, Thomas H. VanDyke, Jennifer Zimmer-Young, Polly E Kin...> ;Journal of Oncology Pharmacy Practice. 2011 Sep 1
• 10 citations
  Phase II trial to evaluate gemcitabine and etoposide for locally advanced or metastatic pancreatic cancer.
  Marianne Melnik, Craig P. Webb, Patrick J. Richardson, Charles R. Luttenton, Alan D. Campbell, Thomas Monroe, Timothy J. O'Rourke, Kathleen J. Yost, Connie M. Szczepan...> ;Molecular Cancer Therapeutics. 2010 Aug 1
• 45 citations
  Phase 1b Study of Motesanib, an Oral Angiogenesis Inhibitor, in Combination with Carboplatin/Paclitaxel and/or Panitumumab for the Treatment of Advanced Non–Small Cell...
  George R. Blumenschein, Karen L. Reckamp, G. Joe Stephenson, Timothy J. O'Rourke, Gregory W. Gladish, Jesse McGreivy, Yu Nien Sun, Yining Ye, Mandy Parson, Alan Sandler> ;Clinical Cancer Research. 2010 Jan 1
• 80 citations
  Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer.
  Polly E Kintzel, Sandra L. Chase, Lisa M Schultz, Timothy J O'Rourke> ;Pharmacotherapy. 2008 Dec 1
• Locally advanced prostate cancer treated with concomitant radiation and 5-fluorouracil: Southwest Oncology Group Study 9024.
  Swanson, G.P., Faulkner, J., Smalley, S.R., Noble, M.J., Stephens, R.L., O'Rourke, T.J., Weiss, G.R., Quick, D.P., Thompson, I.M., Crawford, E.D.> ;J Urol. 2006 Aug
• Safety and pharmacokinetics (PK) of AMG 706, panitumumab, and carboplatin/paclitaxel (CP) for the treatment of patients (pts) with advanced non-small cell lung cancer ...
  Blumenschein G, Sandler A, O'Rourke T, Eschenberg M, Sun Y, Gladish G, Salgia R, Alden C, Herbst RS, Reckamp K> ;J. Clin. Oncol.. 2006-06-20
• Bevacizumab, erlotinib, and imatinib in the treatment of patients with advanced renal cell carcinoma: Update of a multicenter phase II trial.
  Thompson DS, Greco FA, Spigel DR, Sosman JA, Burkett E, O'Rourke TJ, Hart L, Hainsworth JD> ;J. Clin. Oncol.. 2006-06-20
• 153 citations
  Paclitaxel and Gemcitabine Chemotherapy for Advanced Transitional-Cell Carcinoma of the Urothelial Tract: A Phase II Trial of the Minnie Pearl Cancer Research Network
  A. A. Meluch, F. Anthony Greco, Howard A. Burris, Timothy J. O'Rourke, Gregory L. Ortega, Ronald G. Steis, Lisa H. Morrissey, Valerie Johnson, John D. Hainsworth> ;Journal of Clinical Oncology. 2001 Jun 15
• 22 citations
  Phase II trial of paclitaxel by 24-hour continuous infusion for relapsed non-Hodgkin's lymphomas: Southwest Oncology Group trial 9246.
  Oliver W. Press, Michael LeBlanc, Timothy J. O'Rourke, Suzanne Gagnet, R. A. Chapman, Stanley P. Balcerzak, Richard I. Fisher> ;Journal of Clinical Oncology. 1998 Feb 1
• 14 citations
  Pharmacokinetic and phase I studies of brequinar (DUP 785; NSC 368390) in combination with cisplatin in patients with advanced malignancies
  Howard A. Burris, E Raymond, Ahmad Awada, J. G. Kuhn, T. J. O'Rourke, J Brentzel, W Lynch, Susanne King, T. D. Brown, D. D. Von Hoff> ;Investigational New Drugs. 1998 Aug 28
• Interobserver variability in prostate cancer specific survival
  Joseph Y. Clark, Patricia K. Lillis, T. J. O'Rourke, Christina Jones, Betsy Higgins, Ian M. Thompson> ;Urologic Oncology. 1998 Jan 1
• Expectations and experiences of patients with cancer participating in phase I clinical trials.
  Yoder LH, O'Rourke TJ, Etnyre A, Spears DT, Brown TD> ;Oncol Nurs Forum. 1997-06-01
• 6 citations
  Phase I trial of sulofenur (LY186641) given orally on a daily x 21 schedule
  T. D. Brown, O'Rourke Tj, J. G. Kuhn, J. B. Craig, K. Havlin, Burris Ha rd, Cagnola J, Hamilton Jm, Grindey Gb, Satterlee Wg> ;Anti-Cancer Drugs. 1994 Apr 1
• 11 citations
  Testicular relapse in adult acute myelogenous leukemia.
  Don W. Shafer, Howard A. Burris, Timothy J. O'Rourke> ;Cancer. 1992 Sep 15
• Clinical usefulness of an algorithm for the early diagnosis of spinal metastatic disease.
  Redmond J, Friedl KE, Cornett P, Stone M, O'Rourke T, George CB> ;J. Clin. Oncol.. 1988-01-01
• Spinal computed tomography and computed tomographic metrizamide myelography in the early diagnosis of metastatic disease.
  O'Rourke T, George CB, Redmond J, Davidson H, Cornett P, Fill WL, Spring DB, Sobel D, Dabe IB, Karl RD> ;J. Clin. Oncol.. 1986-04-01
• 96 citations
  A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days.
  Wall Jg, Burris Ha rd, Von Hoff Dd, G. Rodriguez, Kneuper-Hall R, Don W. Shaffer, T. J. O'Rourke, Brown T, G. R. Weiss, G. M. Clark> ;Anti-Cancer Drugs. 1992 Aug 1
• New anticancer agents.
  Brown, T. D., Havlin, K. A., Koeller, J. M., Kuhn, J. G., O'Rourke, T. J., Rodriguez, G. I., Weiss, G. R., Von Hoff, D. D.> ;Cancer Chemother Biol Response Modif. 1990
• New anticancer agents.
  Brown, T. D., Burris, H. A., Havlin, K. A., O'Rourke, T. J., Rodriguez, G. I., Wall, J. G., Weiss, G. R.> ;Cancer Chemother Biol Response Modif. 1991
• New anticancer agents.
  Brown, T. D., Burris, H. A., Eckardt, J. R., O'Rourke, T. J., Rodriguez, G. I., Wall, J. G., Weiss, G. R.> ;Cancer Chemother Biol Response Modif. 1992
• Join now to see all